BIO PRODUCTS LABORATORY LIMITED

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +4.9%

  £448,910,817 → £470,695,223

• Cash

  -96.4%

  £47,046,423 → £1,685,729

• Net assets

  +17.5%

  £413,134,485 → £485,445,915

• Employees

  -0.4%

  1,076 → 1,072

• Operating profit

  +47.4%

  £59,395,978 → £87,578,680

• Profit before tax

  +53%

  £60,567,392 → £92,677,730

• Wages

  -0.7%

  £59,662,107 → £59,228,527

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“During 2025 the company demonstrated significant financial growth, finishing the year with strong operating profit. The change to the sales model in the US occurred in May 2025, with transactions routed through Kedrion Biopharma Inc (KBI), had not materially affected the company's cash flow. The company's cash flow budgeting for 2026, as well as testing and pro forma projections for 2027, confirmed its robust and resilient financial position, even under adverse scenarios. In addition, the company operates a cash pooling arrangement with Kedrion S.p.A. Balances held within the cash pooling are payable to BPL on demand, and there are no restrictions or subordination conditions. The directors are comfortable that the Group will be able to repay any balances held as part of the cash pool. Consequently, the cash and cash equivalents at year-end have significantly decreased relative to previous years. Based on what aforementioned, these financial statements have been prepared on the assumption of going concern, as the directors have concluded on the absence of indicators that may cast doubts about the company's ability to meet its obligations in the near future, and specifically in the next 12 months.”

Significant events

• “Effective 1 May 2025, the Company implemented a change to its operational operating model for sales within the United States. Une the recent structure, sales destined for the US market are no longer made directly to third-party distributors by the Company. Instead, all sales for plasma are now processed through Kedrion Biopharma Inc. ('KBI'), a US based Group subsidiary.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.